ATE406915T1 - Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler - Google Patents

Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler

Info

Publication number: ATE406915T1
Authority: AT; Austria
Prior art keywords: pancreatic juice; secretion; regulating; agent; lpa receptor
Prior art date: 2001-07-17

Application number

AT02746091T

Other languages

English (en)

Inventor

Shinji Nakade

Hiroshi Saga

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-17

Filing date

2002-07-16

Publication date

2008-09-15

2002-07-16 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406915T1 publication Critical patent/ATE406915T1/de

Links

210000001819 pancreatic juice Anatomy 0.000 title abstract 4
230000028327 secretion Effects 0.000 title abstract 3
108091006073 receptor regulators Proteins 0.000 title 1
230000001105 regulatory effect Effects 0.000 title 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 3
102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
241000700157 Rattus norvegicus Species 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000001802 infusion Methods 0.000 abstract 1
239000008141 laxative Substances 0.000 abstract 1
230000002475 laxative effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
210000003462 vein Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Non-Alcoholic Beverages (AREA)

AT02746091T 2001-07-17 2002-07-16 Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler ATE406915T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001216133		2001-07-17

Publications (1)

Publication Number	Publication Date
ATE406915T1 true ATE406915T1 (de)	2008-09-15

Family

ID=19050646

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02746091T ATE406915T1 (de)	2001-07-17	2002-07-16	Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler

Country Status (7)

Country	Link
US (2)	US20040171582A1 (de)
EP (1)	EP1415667B1 (de)
JP (1)	JPWO2003007991A1 (de)
AT (1)	ATE406915T1 (de)
DE (1)	DE60228732D1 (de)
ES (1)	ES2312588T3 (de)
WO (1)	WO2003007991A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050113283A1 (en) *	2002-01-18	2005-05-26	David Solow-Cordero	Methods of treating conditions associated with an EDG-4 receptor
EP1550461A1 (de) *	2002-06-26	2005-07-06	Ono Pharmaceutical Co., Ltd.	Mittel zur behandlung chronischer erkrankungen
JP4691988B2 (ja)	2002-10-03	2011-06-01	小野薬品工業株式会社	Ｌｐａ受容体拮抗剤
JP4692281B2 (ja) *	2003-08-05	2011-06-01	味の素株式会社	新規アゾール化合物
US7700792B2 (en)	2003-12-26	2010-04-20	Ono Pharmaceutical Co., Ltd.	Highly active lysophosphatidic acid and method of screening therewith
JPWO2006103750A1 (ja) *	2005-03-29	2008-09-04	日本ハム株式会社	肥満改善用組成物、機能性食品及び医薬用組成物
US9186343B2 (en) *	2007-12-26	2015-11-17	Nanoveson, Llc	Nanoveso™: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases
JP5692746B2 (ja) *	2008-08-07	2015-04-01	国立大学法人長崎大学	全身性疼痛症候群の治療または予防薬
US8455499B2 (en)	2008-12-11	2013-06-04	Amira Pharmaceuticals, Inc.	Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) *	2008-12-15	2010-12-08	Amira Pharmaceuticals Inc	Antagonists of lysophosphatidic acid receptors
GB2470833B (en) *	2009-06-03	2011-06-01	Amira Pharmaceuticals Inc	Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en)	2009-08-04	2011-02-10	Amira Pharmaceuticals, Inc.	Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) *	2009-10-01	2011-10-12	Amira Pharmaceuticals Inc	Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en)	2009-10-01	2011-12-21	Amira Pharmaceuticals Inc	Compounds as Lysophosphatidic acid receptor antagonists
CN103596947A (zh)	2011-04-05	2014-02-19	艾米拉医药股份有限公司	用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
HK1199259A1 (en)	2011-08-15	2015-06-26	Intermune, Inc.	Lysophosphatidic acid receptor antagonists
US20170112861A1 (en) *	2014-04-04	2017-04-27	Osaka University	Drug delivery enhancer comprising substance for activating lysophospholipid receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1865499A (en) *	1997-12-30	1999-07-26	Allelix Biopharmaceuticals Inc.	Identification of lysolipid receptors involved in inflammatory response
US6380177B1 (en) *	1999-06-25	2002-04-30	Atairgin Technologies, Inc.	LPA analogs as agonists of the Edg2 LPA receptor
ATE420878T1 (de) *	2000-02-18	2009-01-15	Kyowa Hakko Kirin Co Ltd	Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
DK1263752T3 (da) *	2000-03-17	2008-04-14	Univ Tennessee Res Corp	LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
WO2002062389A1 (en) *	2001-02-08	2002-08-15	Ono Pharmaceutical Co., Ltd.	Remedies for urinary diseases comprising lpa receptor controlling agents

2002
- 2002-07-16 ES ES02746091T patent/ES2312588T3/es not_active Expired - Lifetime
- 2002-07-16 DE DE60228732T patent/DE60228732D1/de not_active Expired - Fee Related
- 2002-07-16 EP EP02746091A patent/EP1415667B1/de not_active Expired - Lifetime
- 2002-07-16 AT AT02746091T patent/ATE406915T1/de not_active IP Right Cessation
- 2002-07-16 JP JP2003513596A patent/JPWO2003007991A1/ja not_active Withdrawn
- 2002-07-16 US US10/483,815 patent/US20040171582A1/en not_active Abandoned
- 2002-07-16 WO PCT/JP2002/007213 patent/WO2003007991A1/ja not_active Ceased
2008
- 2008-04-30 US US12/112,538 patent/US20080234230A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1415667A4 (de)	2006-04-19
US20040171582A1 (en)	2004-09-02
WO2003007991A1 (en)	2003-01-30
EP1415667B1 (de)	2008-09-03
US20080234230A1 (en)	2008-09-25
ES2312588T3 (es)	2009-03-01
EP1415667A1 (de)	2004-05-06
DE60228732D1 (de)	2008-10-16
JPWO2003007991A1 (ja)	2004-11-04

Similar Documents

Publication	Publication Date	Title
ATE406915T1 (de)	2008-09-15	Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler
DE60321318D1 (de)	2008-07-10	Gewinnung von delta-9 tetrahydrocannabinol
DE60041658D1 (de)	2009-04-09	Zusammensetzung zur förderung des tränenflusses
NZ514203A (en)	2003-02-28	Stabilized bromine solutions, method of manufacture and uses thereof for biofouling control
EP0955294A3 (de)	2000-04-19	Imidazoalkensäure
PE97599A1 (es)	1999-10-12	Sal tartrato de un dipeptido sustituido
DK1104294T3 (da)	2006-02-13	Sammensatninger og Fremgangsmåder til behandling af unormal celleproliferation
MY117251A (en)	2004-06-30	Use of central cannabinoid receptor antagonists for the preparation of drugs
AU640417B2 (en)	1993-08-26	Substituted 5-((tetrazolyl)alkenyl)imidazoles
WO2003053922A3 (en)	2003-10-16	Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
EP0437103A3 (de)	1991-07-24	Substituierte 5-(Alkyl)-carboxamid-Imidazole
TW201922244A (zh)	2019-06-16	治療貧血之組合物及方法
WO2004110380A3 (en)	2005-03-10	Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
HUT56077A (en)	1991-07-29	Process for producing n-(imidazolyl-alkyl)-alanyl derivatives with substituents and pharmaceutical compositions containing them as active components
WO2004041208A3 (en)	2005-02-03	Controlled absorption of mixed thyroyd hormone formulations
BR0010388A (pt)	2002-03-19	Benzoilcetonas substituìdas, processo para a sua preparação e sua aplicação como herbicidas
ATE338763T1 (de)	2006-09-15	Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
Crook et al.	1994	Stimulation of Na+, K+, Cl-cotransport by forskolin-activated adenylyl cyclase in fetal human nonpigmented epithelial cells.
Gallant et al.	1973	The in vivo effect of indomethacin and prostaglandin E2 on ACTH and DBCAMP-induced steroidogenesis in hypophysectomized rats
WO2005051401A3 (en)	2005-09-01	Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
DE60134576D1 (de)	2008-08-07	Arzneimittel zur linderung von darmerkrankungen
EP1575578A4 (de)	2007-10-10	Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung
PL374481A1 (en)	2005-10-31	Remedy for diabetes
Boehm et al.	1996	A somatostatin receptor inhibits noradrenaline release from chick sympathetic neurons through pertussis toxin-sensitive mechanisms: comparison with the action of α2-adrenoceptors
Llontop et al.	2025	The methyl-CpG-binding protein 2 (Mecp2) regulates the hypothalamic mitochondrial function and white adipose tissue lipid metabolism

Legal Events

Date	Code	Title	Description
2009-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties